Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 2, 2026, 2:44 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 63 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Ethinyl Estradiol / Norgestimate Oral Tablet Clear all

Conditions: Healthy
Interventions: lomitapide, EE/norgestimate; Drug
Lead sponsor: Aegerion Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 32 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Infections, Respiratory Tract
Interventions: GSK2140944, GSK2140944 placebo, Moxifloxacin, Moxifloxacin placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Healthy Volunteer
Interventions: Brensocatib, Moxifloxacin, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Infection, Human Immunodeficiency Virus
Interventions: GSK1265744, GSK1265744 matching placebo, Moxifloxacin; Drug
Lead sponsor: ViiV Healthcare; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Asthma, Chronic Obstructive Pulmonary Disease (COPD)
Interventions: CHF5993, CHF5259, Moxifloxacin 400mg, CHF5993 Placebo; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 95 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Metabolic Syndrome X, Insulin Resistance, Obesity, Cardiovascular Diseases
Interventions: Ortho Tri Cyclen; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 46 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Healthy Volunteers
Interventions: CTP-543, Moxifloxacin, Placebo; Drug
Lead sponsor: Concert Pharmaceuticals; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Schizophrenia
Interventions: Elpipodect, Moxifloxacin, Placebo; Drug
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 4
States / cities: Glendale, California • Orange, California • Hallandale, Florida + 1 more

Conditions: Contraception
Interventions: ortho tricyclen, Trinessa; Drug
Lead sponsor: Corewell Health East; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Amount of NKTR-118 in Blood, Variation in the Heart's Electrical Cycle
Interventions: NKTR-118, moxifloxacin, Placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 50 Years · Male only
Enrollment: 45 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cardiac Repolarization, Healthy Volunteers
Interventions: Balinatunfib, Moxifloxacin, Placebo; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Dallas, Texas • Madison, Wisconsin

Conditions: HIV Infections
Interventions: Ortho Tri-Cyclen (ethinyl estradiol + norgestimate), Ortho Tri-Cyclen LO (ethinyl estradiol + norgestimate) + Atazanavir/Ritonavir for 14 days then Ortho Tri-Cyclen for 7 days; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 22 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006
U.S. locations: 1
States / cities: San Diego, California

Conditions: Healthy Subjects
Interventions: GSK1349572 250 mg, Placebo Suspension, Moxifloxacin 400 mg; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 42 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Healthy Volunteer
Interventions: ANG-3777 (Therapeutic Dose), ANG-3777 (Supra-therapeutic Dose), Placebo, Moxifloxacin Hydrochloride; Drug
Lead sponsor: Angion Biomedica Corp; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Pain
Interventions: Suzetrigine, DRSP/EE, NGM/EE; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025
U.S. locations: 1
States / cities: Tempe, Arizona

Conditions: Alzheimer's Disease
Interventions: AZD3293, Placebo, Moxifloxacin; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years · Male only
Enrollment: 52 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Primary Ovarian Insufficiency
Interventions: Hormone Replacement Therapy, Combined Oral Contraceptives; Drug
Lead sponsor: University of Pennsylvania; Other
Eligibility: 14 Years to 45 Years · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Chronic Hepatitis C
Interventions: BMS-790052, Ortho Tri-Cyclen®; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2010
U.S. locations: 2
States / cities: Tempe, Arizona • Austin, Texas

Conditions: Headache, Migraine
Interventions: Erenumab, Ethynil Estradiol/Norgestimate Oral Contraceptive; Drug
Lead sponsor: Amgen; Industry
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 41 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016
U.S. locations: 4
States / cities: Anaheim, California • Cypress, California • Dallas, Texas + 1 more

Conditions: Contraception
Interventions: Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R); Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Healthy Volunteers
Interventions: Ziresovir 125 mg, Ziresovir 500 mg, Placebo, Moxifloxacin hydrochloride tablet 400 mg; Drug
Lead sponsor: Shanghai Ark Biopharmaceutical Co., Ltd.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 34 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024
U.S. locations: 1
States / cities: Glendale, California

Conditions: Hypertension, Mineralocorticoid Receptor Antagonist
Interventions: CS-3150, Moxifloxacin, Placebo matching moxifloxacin tablet, Placebo matching CS-3150; Drug
Lead sponsor: Daiichi Sankyo; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 55 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Retinal Detachment, Achilles Tendon, Aneurysm, Dissecting
Interventions: Oral Fluoroquinolones (FQ), Other Antibiotics, Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure; Drug · Other
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: Not listed
Enrollment: 117,911 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Titusville, New Jersey

Conditions: Healthy
Interventions: Moxifloxacin, ALKS 5461, Placebo; Drug
Lead sponsor: Alkermes, Inc.; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015
U.S. locations: 1
States / cities: Overland Park, Kansas

Search by objective public record fields.

Evaluate the Effect of Ethinyl Estradiol/Norgestimate on the Pharmacokinetics of Lomitapide in Healthy Female Subjects

Placebo and Moxifloxacin Controlled Cardiac Conduction Study of GSK2140944 in Healthy Volunteers

A Study to Investigate the Effects of Brensocatib on QT Interval in Healthy Participants

Study to Evaluate the Effect of GSK1265744 on Cardiac Conduction

A Thorough QT (TQT) Study of CHF5993 pMDI in Healthy Volunteers (HV)

Oral Contraceptives in the Metabolic Syndrome

A Randomized Study to Evaluate the Effects of CTP-543 on the QT/QTc Intervals in Health Volunteers

A Study To Evaluate The Effect Of A Supratherapeutic Dose Of Elpipodect (MK-8189) On The QTc Interval In Participants With Schizophrenia (MK-8189-019)

Side Effect Profiles of Brand Name Versus Generic Oral Contraceptives

A Placebo-controlled Four Way Crossover Study to Asses the Effect of a Single Oral Dose of NKTR-118 on QTc Interval in Healthy Male Subjects

A Study to Evaluate the Effect of Single Oral Dose of Balinatunfib on Cardiac Repolarization in Healthy Adult Participants.

Atazanavir and Ritonavir (ATV/RTV) and an Oral Contraceptive in Healthy Females

Study to Assess Cardiac Conduction of GSK1349572

Study Developed to Evaluate the Effect of ANG-3777 on QT/QTc Interval

Evaluation of the Effect of Suzetrigine (SUZ) on the Pharmacokinetics of Oral Contraceptives in Healthy Female Participants

AZD3293 Thorough QT Study in Healthy Male Volunteers

Hormone Replacement for Premature Ovarian Insufficiency

Study to Assess the Effect of BMS-790052 on the Pharmacokinetics of Ortho Tri-Cyclen® in Healthy Female Subjects

Erenumab (AMG 334) Plus Combined Oral Contraceptive Drug Interaction Study in Healthy Females

Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity

Thorough QT/QTc (TQT) Clinical Study to Evaluate the Effects of Ziresovir on Cardiac Repolarization in Healthy Subjects

The Effect of CS-3150 Exposure on Corrected QT (QTc) Interval Duration in Healthy Volunteers

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers